NK Cell Regulation in Cervical Cancer and Strategies for Immunotherapy

Adriana Gutiérrez-Hoya; Isabel Soto-Cruz

doi:10.3390/cells10113104

journal article Open Access Nov 10, 2021

NK Cell Regulation in Cervical Cancer and Strategies for Immunotherapy

Adriana Gutiérrez-Hoya Isabel Soto-Cruz

Cells Vol. 10 No. 11 pp. 3104 · MDPI AG

View at Publisher Save 10.3390/cells10113104

Abstract

Cervical cancer is one of the most prevalent gynaecological malignancies worldwide and is related to human papillomavirus (HPV) infection, viral persistence, progression, and invasion. Therefore, the immune response is linked to HPV status. Natural killer (NK) cells play a central role against virus-infected cells and tumours through a delicate balance between activating and inhibitory receptors and secretion of cytokines and chemokines. These cells also play a crucial role in tumour immunosurveillance. For these reasons, there is growing interest in harnessing NK cells as an immunotherapy for cervical cancer. These studies are diverse and include many strategies such as transferring activated autologous or allogeneic NK cells, improving the activation and cytolytic activity of NK cells using cytokines or analogues and modifying chimeric antigen receptors to increase specificity and targeting NK cells. However, research regarding the application of NK cells in immunotherapy is limited. This article focuses on recent discoveries about using NK cells to prevent and treat cervical cancer and the possibility of cellular immunotherapy becoming one of the best strategies to exploit the immune system to fight tumours.

Topics

No keywords indexed for this article. Browse by subject →

References

101

[1]

Bansal "Human Papillomavirus-Associated Cancers: A Growing Global Problem" Int. J. Appl. Basic Med. Res. (2016) 10.4103/2229-516x.179027

[2]

Wang "Involvement of Human Papillomaviruses in Cervical Cancer" Front. Microbiol. (2018) 10.3389/fmicb.2018.02896

[3]

Saraiya "US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines" JNCI J. Natl. Cancer Inst. (2015) 10.1093/jnci/djv086

[4]

Wendland "Prevalence of HPV Infection among Sexually Active Adolescents and Young Adults in Brazil: The POP-Brazil Study" Sci. Rep. (2020) 10.1038/s41598-020-61582-2

[5]

Dunne "Prevalence of HPV Infection Among Females in the United States" JAMA (2007) 10.1001/jama.297.8.813

[6]

Markowitz "Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010" J. Infect. Dis. (2013) 10.1093/infdis/jit192

[7]

McQuillan, G., and Unger, E.R. (2017). Prevalence of HPV in Adults Aged 18–69: United States, 2011–2014.

[8]

Shanmugasundaram, S., and You, J. (2017). Targeting Persistent Human Papillomavirus Infection. Viruses, 9. 10.3390/v9080229

[9]

"Immunology of Cervical Cancer" Rev. Investig. Clínica (2020)

[10]

Christensen "HPV Disease Transmission Protection and Control" Microb. Cell. (2016) 10.15698/mic2016.09.530

[11]

Zhou "Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System" Front. Oncol. (2019) 10.3389/fonc.2019.00682

[12]

Role of Innate Immunity against Human Papillomavirus (HPV) Infections and Effect of Adjuvants in Promoting Specific Immune Response

Alfredo Amador-Molina, José Hernández-Valencia, Edmundo Lamoyi et al.

Viruses 2013 10.3390/v5112624

[13]

Sasagawa "Immune Responses against Human Papillomavirus (HPV) Infection and Evasion of Host Defense in Cervical Cancer" J. Infect. Chemother. (2012) 10.1007/s10156-012-0485-5

[14]

Zhang "Targeting Natural Killer Cells for Tumor Immunotherapy" Front. Immunol. (2020) 10.3389/fimmu.2020.00060

[15]

Liu "NK Cell-Based Cancer Immunotherapy: From Basic Biology to Clinical Development" J. Hematol. Oncol. (2021) 10.1186/s13045-020-01014-w

[16]

"Chemotherapy and Molecular Therapy in Cervical Cancer" Rep. Pract. Oncol. Radiother. (2018) 10.1016/j.rpor.2018.09.002

[17]

Peiretti "Management of Recurrent Cervical Cancer: A Review of the Literature" Surg. Oncol. (2012) 10.1016/j.suronc.2011.12.008

[18]

Hung, M.-C., Liu, M.-T., Cheng, Y., and Wang, J.-D. (2014). Estimation of Savings of Life-Years and Cost from Early Detection of Cervical Cancer: A Follow-up Study Using Nationwide Databases for the Period 2002–2009. BMC Cancer, 14. 10.1186/1471-2407-14-505

[19]

Burd "Human Papillomavirus and Cervical Cancer" Clin. Microbiol. Rev. (2003) 10.1128/cmr.16.1.1-17.2003

[20]

Gheit "Mucosal and Cutaneous Human Papillomavirus Infections and Cancer Biology" Front. Oncol. (2019) 10.3389/fonc.2019.00355

[21]

Graham "The Human Papillomavirus Replication Cycle, and Its Links to Cancer Progression: A Comprehensive Review" Clin. Sci. (2017) 10.1042/cs20160786

[22]

Schiffman "Carcinogenic Human Papillomavirus Infection" Nat. Rev. Dis. Primers (2016) 10.1038/nrdp.2016.86

[23]

Spriggs, C., and Laimins, L. (2017). Human Papillomavirus and the DNA Damage Response: Exploiting Host Repair Pathways for Viral Replication. Viruses, 9. 10.3390/v9080232

[24]

"Oral Manifestations of Human Papillomavirus Infections" Eur. J. Oral. Sci. (2018) 10.1111/eos.12538

[25]

Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy

Asmita Pal, Rita Kundu

Frontiers in Microbiology 2020 10.3389/fmicb.2019.03116

[26]

Middleton "Organization of Human Papillomavirus Productive Cycle during Neoplastic Progression Provides a Basis for Selection of Diagnostic Markers" J. Virol. (2003) 10.1128/jvi.77.19.10186-10201.2003

[27]

Trimble "Spontaneous Regression of High-Grade Cervical Dysplasia: Effects of Human Papillomavirus Type and HLA Phenotype" Clin. Cancer Res. (2005) 10.1158/1078-0432.ccr-04-2599

[28]

Cho "Type-Specific Persistence or Regression of Human Papillomavirus Genotypes in Women with Cervical Intraepithelial Neoplasia 1: A Prospective Cohort Study" Obs. Gynecol. Sci. (2015) 10.5468/ogs.2015.58.1.40

[29]

Lebre "Human Keratinocytes Express Functional Toll-Like Receptor 3, 4, 5, and 9" J. Investig. Dermatol. (2007) 10.1038/sj.jid.5700530

[30]

Nasu "Pattern Recognition via the Toll-Like Receptor System in the Human Female Genital Tract" Mediat. Inflamm. (2010) 10.1155/2010/976024

[31]

Tamoutounour "Keratinocyte-Intrinsic MHCII Expression Controls Microbiota-Induced Th1 Cell Responses" Proc. Natl. Acad. Sci. USA (2019) 10.1073/pnas.1912432116

[32]

Donadi "Immune Cellular Response to HPV: Current Concepts" Braz. J. Infect. Dis. (2004)

[33]

Hibma "The Immune Response to Papillomavirus During Infection Persistence and Regression" Open Virol. J. (2012) 10.2174/1874357901206010241

[34]

Mah "Metabolic Regulation of Natural Killer Cell IFN-γ Production" Crit. Rev. Immunol. (2016) 10.1615/critrevimmunol.2016017387

[35]

Ferns "Classical and Non-Classical HLA Class I Aberrations in Primary Cervical Squamous- and Adenocarcinomas and Paired Lymph Node Metastases" J. Immunother. Cancer (2016) 10.1186/s40425-016-0184-3

[36]

Cho, H., Chung, J.-Y., Kim, S., Braunschweig, T., Kang, T.H., Kim, J., Chung, E.J., Hewitt, S.M., and Kim, J.-H. (2014). MICA/B and ULBP1 NKG2D Ligands Are Independent Predictors of Good Prognosis in Cervical Cancer. BMC Cancer, 14. 10.1186/1471-2407-14-957

[37]

Utami "NK-Cell Count and Its Function in Producing Interferon Gamma Associated with the Cervical Cancer Natural History" Glob. J. Reprod. Med. (2018)

[38]

Paul "The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy" Front. Immunol. (2017) 10.3389/fimmu.2017.01124

[39]

Miyazato "Pharmacological Targeting of Natural Killer Cells for Cancer Immunotherapy" Cancer Sci. (2020) 10.1111/cas.14418

[40]

Long "Negative Signalling by Inhibitory Receptors: The NK Cell Paradigm" Immunol. Rev. (2008) 10.1111/j.1600-065x.2008.00660.x

[41]

Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset

Megan A. Cooper, Todd A. Fehniger, Sarah C. Turner et al.

Blood 2001 10.1182/blood.v97.10.3146

[42]

Cooper "The Biology of Human Natural Killer-Cell Subsets" Trends Immunol. (2001) 10.1016/s1471-4906(01)02060-9

[43]

Jenkins "Natural Killer Cells in Cervical Intraepithelial Neoplasia and Human Papillomavirus Infection" BJOG Int. J. Obstet. Gynaecol. (1987) 10.1111/j.1471-0528.1987.tb03763.x

[44]

Alves "Linfócitos CD4, CD8 e células NK no estroma da cérvice uterina de mulheres infectadas pelo papilomavírus humano" Rev. Soc. Bras. Med. Trop. (2010) 10.1590/s0037-86822010000400018

[45]

Zhang "Human Papillomavirus Type 16 Disables the Increased Natural Killer Cells in Early Lesions of the Cervix" J. Immunol. Res. (2019) 10.1155/2019/9182979

[46]

Textor "Activating NK Cell Receptor Ligands Are Differentially Expressed during Progression to Cervical Cancer" Int. J. Cancer (2008) 10.1002/ijc.23733

[47]

Vaquer "Clinical Implications of Natural Killer (NK) Cytotoxicity in Patients with Squamous Cell Carcinoma of the Uterine Cervix" Gynecol. Oncol. (1990) 10.1016/0090-8258(90)90114-z

[48]

Senju "Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy" Int. J. Biol. Sci. (2018) 10.7150/ijbs.22809

[49]

Lee "Both E6 and E7 Oncoproteins of Human Papillomavirus 16 Inhibit IL-18-Induced IFN-γ Production in Human Peripheral Blood Mononuclear and NK Cells" J. Immunol. (2001) 10.4049/jimmunol.167.1.497

[50]

Song "HPV E7 Inhibits Cell Pyroptosis by Promoting TRIM21-Mediated Degradation and Ubiquitination of the IFI16 Inflammasome" Int. J. Biol. Sci. (2020) 10.7150/ijbs.50074

Showing 50 of 101 references

Cited By

67

From Inflammation to Malignancy: The Link Between Endometriosis and Gynecological Cancers

Karolina Kłodnicka, Aleksandra Michalska · 2025

International Journal of Molecular...

USP7 inhibits TIMP2 by up-regulating the expression of EZH2 to activate the NF-κB/PD-L1 axis to promote the development of cervical cancer

Na Li, Feng Geng · 2022

Cellular Signalling

Metrics

67

Citations

101

References

Details

Published: Nov 10, 2021
Vol/Issue: 10(11)
Pages: 3104
License: View

Authors

A

Adriana Gutiérrez-Hoya

Molecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, FES Zaragoza, National University of Mexico, Batalla 5 de Mayo S/n Col. Ejército de Oriente, Mexico City 09230, Mexico; Cátedra CONACYT, CONACYT, Avenida Insurgentes Sur 1582, Col. Crédito Constructor Del. Benito Juárez, Mexico City 03940, Mexico

I

Isabel Soto-Cruz

Molecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, FES Zaragoza, National University of Mexico, Batalla 5 de Mayo S/n Col. Ejército de Oriente, Mexico City 09230, Mexico

Funding

National University of Mexico Award: PAPIIT IN222121, DGAPA UNAM

Cite This Article

Adriana Gutiérrez-Hoya, Isabel Soto-Cruz (2021). NK Cell Regulation in Cervical Cancer and Strategies for Immunotherapy. Cells, 10(11), 3104. https://doi.org/10.3390/cells10113104

NK Cell Regulation in Cervical Cancer and Strategies for Immunotherapy

You May Also Like